We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.85B
AUM Growth
+$217M
Cap. Flow
+$578M
Cap. Flow %
8.44%
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$112M
2
APLS
Apellis Pharmaceuticals
APLS
+$78.4M
3
PEN icon
Penumbra
PEN
+$62.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$54.4M
5
ARGX icon
argenx
ARGX
+$53.9M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$153M
2
INMD icon
InMode
INMD
+$19.9M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$17.3M
4
AGEN
Agenus
AGEN
+$12.9M
5
GH icon
Guardant Health
GH
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.33%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
76
DELISTED
Adverum Biotechnologies
ADVM
$13.3M 0.19%
755,482
+7,106
+0.9% +$142K
BWAY
77
Brainsway
BWAY
$622M
$12.3M 0.18%
3,204,762
– –
LJPC
78
DELISTED
La Jolla Pharmaceutical Company
LJPC
$10.8M 0.16%
2,327,903
– –
NEO icon
79
NeoGenomics
NEO
$2.13B
$10.6M 0.16%
311,111
– –
CLSD
80
DELISTED
Clearside Biomedical
CLSD
$10.5M 0.15%
253,735
-26,716
-10% -$1.73M
OSUR icon
81
OraSure Technologies
OSUR
$279M
$10M 0.15%
1,154,380
-20,342
-2% -$201K
ABUS icon
82
Arbutus Biopharma
ABUS
$915M
$9.74M 0.14%
2,504,493
-2,228,830
-47% -$8.66M
XGN icon
83
Exagen
XGN
$166M
$9.55M 0.14%
821,414
– –
GTH
84
DELISTED
Genetron Holdings Limited ADS
GTH
$8.67M 0.13%
473,965
-83,333
-15% -$2.76M
URGN icon
85
UroGen Pharma
URGN
$2.29B
$8.15M 0.12%
857,464
– –
ROIV icon
86
Roivant Sciences
ROIV
$26.2B
$8.09M 0.12%
+802,717
New +$6.68M
NYXH
87
Nyxoah
NYXH
$147M
$7.93M 0.12%
344,911
– –
VINC
88
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$7.55M 0.11%
37,062
-438
-1% -$109K
MRUS
89
DELISTED
Merus
MRUS
$6.24M 0.09%
+196,231
New +$5.54M
RACB
90
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$6.19M 0.09%
637,000
– –
BLSA
91
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$6M 0.09%
612,500
– –
NAUT icon
92
Nautilus Biotechnolgy
NAUT
$115M
$5.7M 0.08%
1,100,000
– –
SMIHU
93
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
$4.97M 0.07%
500,000
– –
ARYD
94
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$4.96M 0.07%
500,000
– –
PRCT icon
95
Procept Biorobotics
PRCT
$1.17B
$4.86M 0.07%
194,136
– –
ARYE
96
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$4.85M 0.07%
500,000
– –
IMTX icon
97
Immatics
IMTX
$1.32B
$4.7M 0.07%
350,000
– –
BMEA icon
98
Biomea Fusion
BMEA
$91.3M
$4.42M 0.06%
593,846
-236,948
-29% -$2.51M
SOPH icon
99
SOPHiA GENETICS
SOPH
$647M
$4.23M 0.06%
300,000
– –
FVAM
100
DELISTED
5:01 Acquisition Corp
FVAM
$3.86M 0.06%
392,000
– –
2 3
4
5 6

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2021 Portfolio in Review

As of Q4 2021, RTW Investments held 136 positions worth $6.85B, up 3.3% from $6.63B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

RTW Investments deployed $578M of net new capital in Q4 2021, opening 16 new positions and adding to 27 existing holdings. Its largest new stake was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $17.3M trimmed.

  • RTW Investments's largest Q4 2021 buy was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.
  • RTW Investments added most to Penumbra in Q4 2021, an estimated $62.3M increase.
  • RTW Investments's biggest Q4 2021 reduction was IDEAYA Biosciences, cutting an estimated $17.3M.
  • RTW Investments fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $153M.
  • RTW Investments's ten largest holdings make up 38% of its $6.85B portfolio in Q4 2021.
  • RTW Investments opened 16 new positions and closed 11 in Q4 2021.
  • RTW Investments's portfolio value rose 3.3% quarter-over-quarter to $6.85B.

Based on RTW Investments's 13F filing for Q4 2021, filed 14 Feb 2022.